James Ede-Golightly - 14 Dec 2025 Form 3 Insider Report for Silence Therapeutics plc (SLN)

Role
Director
Signature
/s/ Rhonda Hellums, Attorney-in-Fact
Issuer symbol
SLN
Transactions as of
14 Dec 2025
Net transactions value
$0
Form type
3
Filing time
22 Dec 2025, 18:02:31 UTC
Previous filing
06 Jan 2025
Next filing
22 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ede-Golightly James Director C/O SILENCE THERAPEUTICS PLC, 12 HAMMERSMITH GROVE, LONDON, UNITED KINGDOM /s/ Rhonda Hellums, Attorney-in-Fact 22 Dec 2025 0002048873

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLN Ordinary Shares 15,000 14 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLN Share Option (Right to Buy) 14 Dec 2025 Ordinary Shares 48,000 $7.87 Direct F1
holding SLN Share Option (Right to Buy) 14 Dec 2025 Ordinary Shares 27,999 $5.13 Direct F1
holding SLN Share Option (Right to Buy) 14 Dec 2025 Ordinary Shares 22,668 $5.90 Direct F1
holding SLN Share Option (Right to Buy) 14 Dec 2025 Ordinary Shares 6,666 $2.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.